Where does albuminuria come from in diabetic kidney disease?

Current Diabetes Reports

Volumn 8, Issue 6, 2008, Pages 477-485

  Comper, Wayne D ^a   Russo, Leileata M ^b  

^a MONASH UNIVERSITY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FETUIN A; GLYCOSAMINOGLYCAN; HEMOPEXIN; HEPARAN SULFATE; IMMUNOGLOBULIN G; LYSOSOME ENZYME; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME DEGRADATION; ENZYMURIA; GLOMERULAR DYSFUNCTION; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MULTIPHOTON MICROSCOPY; NONHUMAN; PATHOGENESIS; PEPTIDURIA; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; PROTEINURIA; REVIEW; URINARY EXCRETION;

ALBUMINS; ALBUMINURIA; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY GLOMERULUS; MODELS, BIOLOGICAL;

EID: 63149123654     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0082-2     Document Type: Review

References (79)

1. Satchell SC, Tooke JE: What is the mechanism of microalbuminuria in diabetes: A role for the glomerular endothelium? Diabetologia 2008, 51: 714-725.
2. Ziyadeh FN, Wolf G: Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008, 4: 39-45.
3. Jefferson JA, Shankland SJ, Pichler RH: Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney Int 2008, 74: 22-36.
4. Asgeirsson D, Venturoli D, Fries E, et al.: Glomerular sieving of three neutral polysaccharides, polyethylene oxide and bikunin in rat. Effects of molecular size and conformation. Acta Physiol 2007, 191: 237-246.
5. Blouch K, Deen WM, Fauvel JP, et al.: Molecular configuration and glomerular size selectivity in healthy and nephrotic humans. Am J Physiol 1997, 273: F430-F437.
6. Greive KA, Nikolic-Paterson DJ, Guimaràes MA, et al.: Glomerular permselectivity factors are not responsible for the increase in fractional clearance of albumin in rat glomerulonephritis. Am J Pathol 2001, 159: 1159-1170.
7. Guimaràes MAM, Nikolovski J, Pratt LM, et al.: Anomalous fractional clearance of negatively charged Ficoll relative to uncharged Ficoll. Am J Physiol 2003, 285: F1118-F1124.
8. Lemley KV, Blouch K, Abdullah I, et al.: Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 2000, 11: 2095-2105.
9. Myers BD, Winetz JA, Chui F, Michaels AS: Mechanisms of proteinuria in diabetic nephropathy: A study of glomerular barrier function. Kidney Int 1982, 21: 633-641.
10. Oliver JD, Anderson S, Troy JL, et al.: Determination of glomerular size-selectivity in the normal rat with Ficoll. J Am Soc Nephrol 1992, 3: 214-228.
11. Tojo A, Endou H: Intrarenal handling of proteins in rats using fractional micropuncture technique. Am J Physiol 1992, 263: F601-F606.
12. Chang RLS, Deen WM, Robertson CR, Brenner BM: Permselectivity of the glomerular capillary wall. III. Restricted transport of polyanions. Kidney Int 1975, 8: 212-218.
13. Vyas SV, Burne MJ, Pratt LM, Comper WD: Glomerular processing of dextran sulphate. Arch Biochem Biophys 1996, 332: 205-212.
14. Tay M, Comper WD, Singh AK: Charge selectivity in kidney ultrafiltration is associated with glomerular uptake of transport probes. Am J Physiol 1991, 260: F549-F554.
15. Comper WD, Tay M, Wells X, Dawes J: Desulphation of dextran sulphate during kidney ultrafiltration. Biochem J 1994, 297: 31-34.
16. Asgeirsson D, Rippe B, Venturoli D, Rippe C: Increased glomerular permeability to negatively charged Ficoll relative to neutral Ficoll in rats. Am J Physiol 2006, 291: F1083-F1089.
17. Clavant SP, Comper WD: Urinary clearance of albumin is critically determined by its tertiary structure. J Lab Clin Med 2003, 142: 372-384.
18. Ohlson M, Sörensson J, Lindström K, et al.: Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules. Am J Physiol 2001, 281: F103-F113.
19. Schaeffer RC, Gratrix ML, Mucha DR, Carbajal JM: The rat glomerular filtration barrier does not show negative charge selectivity. Microcirculation 2002, 9: 329-342.
20. Comper WD, Osicka TM, Russo LM: Renal filtration, transport, and metabolism of albumin and albuminuria. In The Kidney: Physiology and Pathophysiology. Edited by Alpern R, Hebert S. San Diego, CA: Elsevier; 2007:2081-2112.
21. Edmond E, Ogston AG: An approach to the study of phase separation in ternary aqueous systems. Biochem J 1968, 109: 569-576.
22. Rosenzweig LG, Kanwar YS: Removal of sulfated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. Lab Invest 1982, 47: 177-184.
23. Chen S, Wassenhove-McCarthy D, Yamaguchi Y, et al.: Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. Kidney Int 2008, 74: 289-299.
24. Harvey SJ, Jarad G, Cunningham J, et al.: Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007, 171: 139-152.
25. Rossi M, Morita H, Sormunen R, et al.: Heparan sulfate chains of perlecan are indispensable in the lens capsule but not the kidney. EMBO J 2003, 22: 236-245.
26. van den Born J, Pisa B, Bakker MA, et al.: No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy. J Biol Chem 2006, 281: 29606-29613.
27. van den Hoven MJ, Wijnhoven TJ, Li JP, et al.: Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int 2008, 73: 278-287.
28. Adal Y, Smit MF, Osicka TM, Comper WD: Albumin interaction with the glomerular capillary wall in vitro. Kidney Int 1995, 47: 1031-1038.
29. Kramer A, van den Hoven M, Rops A, et al.: Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 2006, 17: 2513-2520.
30. Levidiotis V, Freeman C, Tikellis C, et al.: Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 2004, 15: 68-78.
31. Maxhimer JB, Somenek M, Rao G, et al.: Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: A potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005, 54: 2172-2178.
32. van den Hoven MJ, Rops AL, Vlodavsky I, et al.: Heparanase in glomerular diseases. Kidney Int 2007, 72: 543-548.
33. Jeansson M, Granqvist AB, Nyström JS, Haraldsson B: Functional and molecular alterations of the glomerular barrier in long-term diabetes in mice. Diabetologia 2006, 49: 2200-2209.
34. CompNr WD, Haraldsson B, Deen WM: Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 2008, 19: 427-432.
35. Rippe C, Asgeirsson D, Venturoli D, et al.: Effects of glomerular filtration rate on Ficoll sieving coefficients in rats. Kidney Int 2006, 69: 1326-1332.
36. Russo LM, Sandoval RM, McKee M, et al.: The normal kidney filters nephrotic levels of albumin that is retrieved by the proximal tubule cell: Retrieval is disrupted in nephrotic states. Kidney Int 2007, 71: 504-513.
37. Russo LM, Sandoval RM, McKee M, et al.: Glomerular permeability of albumin and its tubular uptake in experimental diabetes. J Am Soc Nephrol 2008, (in press).
38. Fox JG, Quin JD, Paterson KR, et al.: Glomerular charge selectivity in type 1 (insulin-dependent) diabetes mellitus. Diabet Med 1995, 12: 387-391.
39. Lemley KV, Blouch K, Abdullah I, et al.: Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 2000, 11: 2095-2105.
40. Ruggenenti P, Mosconi L, Sangalli F, et al.: Glomerular size selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int 1999, 55: 984-994.
41. Scandling JD, Myers BD: Glomerular size-selectivity and microalbuminuria in early diabetic glomerular disease. Kidney Int 1992, 41: 840-846.
42. Russo LM, Osicka TM, Brammar GC, et al.: Renal processing of albumin in diabetes and hypertension in rats. Am J Nephrol 2003, 23: 61-70.
43. Comper WD, Hilliard LM, Nikolic-Paterson D, Russo LM: Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008 Jun 25 (Epub ahead of print).
44. Park CH, Maack T: Albumin absorption and catabolism by isolated perfused proximal convoluted tubules of the rabbit. J Clin Invest 1984, 73: 767-777.
45. Eppel GA, Osicka TM, Pratt LM, et al.: The return of glomerular filtered albumin to the rat renal vein. Kidney Int 1999, 55: 1861-1870.
46. Hilliard LM, Russo LM, Comper WD: Insights into the relationship between hypertension and albuminuria. Curr Hypertens Rev 2007, 3: 29-37.
47. Birn H, Christensen EI: Renal albumin absorption in physiology and pathology. Kidney Int 2006, 69: 440-449.
48. Greive KA, Balazs ND, Comper WD: Protein fragments in urine have been considerably underestimated by various protein assays. Clin Chem 2001, 47: 1717-1719.
49. Greive KA, Osicka TM, Russo LM, Comper WD: Nephroticlike proteinuria in experimental diabetes. Am J Nephrol 2003, 23: 38-46.
50. Gudehithlu KP, Pegoraro AA, Dunea G, et al.: Degradation of albumin by the renal proximal tubule cells and the subsequent fate of its fragments. Kidney Int 2004, 65: 2113-2122.
51. Hilliard LM, Osicka TM, Clavant S, et al.: Characterisation of the urinary albumin degradation pathway in the isolated perfused rat kidney. J Lab Clin Med 2006, 147: 36-44.
52. Osicka TM, Comper WD: Protein degradation during renal passage in normal kidneys is inhibited in experimental albuminuria. Clin Sci 1997, 93: 65-72.
53. Strong KJ, Osicka TM, Comper WD: Urinary peptide excretion by non-diabetic volunteers and diabetic patients. J Lab Clin Med 2005, 145: 239-246.
54. Osicka TM, Pratt LM, Comper WD: Glomerular capillary wall permeability to albumin and horseradish peroxidase. Nephrology 1996, 2: 199-212.
55. Bando Y, Kominami E, Katunuma N: Purification and tissue distribution of rat cathepsin L. J Biochem (Tokyo) 1986, 100: 35-42.
56. Hilliard LM, Russo LM, Comper WD: Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and heart. Am J Nephrol 2008 (in press).
57. Kominami E, Tsukahara T, Bando Y, Katunuma N: Distribution of cathepsins B and H in rat tissues and peripheral blood cells. J Biochem (Tokyo) 1985, 98: 87-93.
58. Nielsen R, Courtoy PJ, Jacobsen C, et al.: Endocytosis provides a major alternative pathway for lysosomal biogenesis in kidney proximal tubular cells. Proc Natl Acad Sci U S A 2007, 104: 5407-5412.
59. Clavant SP, Forbes JM, Thallas V, et al.: Reversible angiotensin II-mediated albuminuria in rat kidneys is dynamically associated with cytoskeletal organization. Nephron Physiol 2003, 93: 51-60.
60. Tojo A, Onozato ML, Kurihara H, et al.: Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 2003, 26: 413-419.
61. Brezniceanu ML, Liu F, Wei CC, et al.: Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 2007, 71: 912-923.
62. Liu F, Brezniceanu ML, Wei CC, et al.: Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol 2008, 19: 269-280.
63. Russo LM, Brammar GC, Jerums G, et al.: The effect of ramipril on albumin excretion in diabetes and hypertension: The role of increased lysosomal activity and decreased transforming growth factor-beta expression. J Hypertens 2003, 21: 419-428.
64. Aronoff SL, Schnider S, Smeltzer J, et al.: Urinary excretion and renal clearance of specific plasma proteins in diabetes of short and long duration. Diabetes 1981, 30: 656-663.
65. Kantarci S, Al-Gazali L, Hill RS, et al.: Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Gen 2007, 39: 957-959.
66. Osicka TM, Houlihan CA, Chan JG, et al.: Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 2000, 49: 1579-1584.
67. Rabkin R, Fervenza FC: Renal hypertrophy and kidney disease in diabetes. Diabetes Metab Rev 1996, 12: 217-241.
68. Schenk O, Ling H, Sebekova K, et al.: High glucose media enhance the responsiveness of tubular cells to growth promoters: Effect on lysosomal cathepsins and protein degradation. Miner Electrolyte Metab 1998, 24: 254-260.
69. Russo LM, Osicka TM, Bonnet F, et al.: Albuminuria in hypertension is linked to altered lysosomal activity and TGF-beta1 expression. Hypertension 2002, 39: 281-286.
70. Gekle M, Knaus P, Nielsen R, et al.: Transforming growth factor-beta1 reduces megalin-and cubulin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol 2003, 15: 471-481.
71. Russo LM, del Re E, Brown D, Lin HY: Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: Amelioration by soluble TGF-beta type II receptor. Diabetes 2007, 56: 380-388.
72. Osicka TM, Kiriazis Z, Pratt LM, et al.: Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats. Diabetologia 2001, 44: 230-236.
73. Bjorck S, Mulec H, Johnsen SA, et al.: Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ 1990, 300: 904-907.
74. Williams KJ, Qiu G, Usui HK, et al.: Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol 2007, 171: 1441-1450.
75. Hein S, Arnon E, Kostin S, et al.: Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003, 107: 984-991.
76. Suzuki H, Schaefer L, Ling H, et al.: Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: Potential role of lysosomal proteinases. Am J Nephrol 1995, 15: 129-136.
77. Flather MD, Yusuf S, Køber L, et al.: Long-term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000, 355: 1575-1581.
78. Kim S, Yoshiyama M, Izumi Y, et al.: Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001, 103: 148-154.
79. Nakamura Y, Yoshiyama M, Omura T, et al.: Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodelling in rat myocardial infarction. Cardiovasc Res 2003, 57: 48-54.